Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Change In Receivables?

Shanghai Kaibao Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Shanghai Kaibao Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Shanghai Kaibao Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥100 Mil. It means Shanghai Kaibao Pharmaceutical Co's Accounts Receivable declined by ¥100 Mil from Dec. 2022 to Dec. 2023 .

Shanghai Kaibao Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥348 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shanghai Kaibao Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 66.87.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shanghai Kaibao Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was ¥752 Mil.

Shanghai Kaibao Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Change In Receivables Chart

Shanghai Kaibao Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

57.45

137.88

-74.90

58.32

99.53

Shanghai Kaibao Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Shanghai Kaibao Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shanghai Kaibao Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	348.479	/	475.497	*	91
=	66.87

2. In Ben Graham's calculation of liquidation value, Shanghai Kaibao Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Shanghai Kaibao Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	918.49	-	507.294	+	0.75 * 348.479	+	0.5 * 159.194
=	752

Shanghai Kaibao Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Change In Receivables

Traded in Other Exchanges

N/A

Address

88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401

Website

http://www.xykb.com

Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.

Executives

Liu Shao Yong	Supervisors
Ren Li Wang	Secretary Dong
Zhang Tao	Executives
Mu Jing Wei	Director
Li Xiu Hai	Directors, executives
Zhang Lian Xin	Supervisors
Han Jing	Independent director
Wang Guo Ming	Directors, executives
Wang Chong Bang	Executives
Liu Yi Shan	Director
Li Qing Wei	Independent director
Mu Lai An	Director
Zhu Ying Jun	Executives
Chang Qing Ling	Supervisors
Zhang Peng	Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines